FDA Strengthens Invokana, Farxiga Acute Kidney Injury Risk Warnings

(June 20, 2016, 9:38 AM EDT) -- SILVER SPRING, Md. — The Food and Drug Administration on June 14 said it has strengthened the existing warnings for the risk of acute kidney injury on the diabetes drugs Invokana (canagliflozin) and Farxiga (dapaglifozin).

The FDA said patients taking either drug should seek immediate medical attention if they experience signs and symptoms of acute kidney injury, which includes decreased urine or swelling of the legs or feet. It said that before prescribing Invokana or Farxiga, health care practitioners should consider factors that may predispose patients...
To view the full article, register now.